RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
VIVA Biotech Holdings Stock

VIVA Biotech Holdings Liabilities 2024

VIVA Biotech Holdings Liabilities

3.76 B CNY

Ticker

1873.HK

ISIN

KYG9390W1015

WKN

A2PH5Q

In 2024, VIVA Biotech Holdings's total liabilities amounted to 3.76 B CNY, a -12.84% difference from the 4.32 B CNY total liabilities in the previous year.

VIVA Biotech Holdings Aktienanalyse

What does VIVA Biotech Holdings do?

VIVA Biotech Holdings is a Chinese company specializing in the development of pharmaceuticals. It was listed on the Hong Kong Stock Exchange in 2018 and is headquartered in Shanghai. The company started as a small start-up in 2013 but has quickly become one of the industry leaders in pharmaceutical discovery and development. VIVA Biotech Holdings' business model revolves around creating a shared ecosystem for biotechnology start-ups and their customers. The company offers a wide range of services, including target molecule identification and validation, drug candidate optimization, and speeding up the timeline for clinical trials and commercialization. One key aspect of VIVA Biotech Holdings' business model is its VIVA Accelerator programs, which support and foster promising early-stage biotechnology start-ups. These programs provide start-ups with access to state-of-the-art facilities, expert advice, and funding opportunities. The company also operates several divisions focused on the discovery and development of new pharmaceuticals. These divisions include drug candidate synthesis, screening platforms for identifying drug candidates, and structural elucidation of proteins and other molecules. A major focus of VIVA Biotech Holdings is the development of cancer treatments. The company has developed a wide range of drug candidates that specifically target and destroy cancer cells. This includes both small molecules and biological drugs. In addition to cancer research, VIVA Biotech Holdings is also involved in the discovery and development of drugs for other diseases such as inflammatory and metabolic disorders. The company works closely with its customers and partners to develop targeted treatment options. Overall, VIVA Biotech Holdings has achieved an impressive track record in drug discovery and development in recent years. The company has developed a wide range of drug candidates at various stages of clinical development that have the potential to revolutionize the treatment of cancer and other diseases. As a company, VIVA Biotech Holdings is also committed to promoting the biotechnology sector and supporting start-ups and young companies. It is an important player in the Chinese biotech industry and an emerging company in the global pharmaceutical development market. VIVA Biotech Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing VIVA Biotech Holdings's Liabilities

VIVA Biotech Holdings's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating VIVA Biotech Holdings's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing VIVA Biotech Holdings's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

VIVA Biotech Holdings's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in VIVA Biotech Holdings’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about VIVA Biotech Holdings stock

What is the level of liabilities of VIVA Biotech Holdings this year?

VIVA Biotech Holdings has a debt balance of 3.76 B CNY this year.

What were the liabilities of VIVA Biotech Holdings compared to the previous year?

The liabilities of VIVA Biotech Holdings have increased by -12.84% dropped compared to the previous year.

What are the consequences of high debt for investors of VIVA Biotech Holdings?

High liabilities can pose a risk for investors of VIVA Biotech Holdings, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in VIVA Biotech Holdings?

Low liabilities mean that VIVA Biotech Holdings has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of VIVA Biotech Holdings affect the company?

An increase in liabilities of VIVA Biotech Holdings can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of VIVA Biotech Holdings affect the company?

A decrease in the liabilities of VIVA Biotech Holdings can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of VIVA Biotech Holdings?

Some factors that can influence the liabilities of VIVA Biotech Holdings include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of VIVA Biotech Holdings so important for investors?

The liabilities of VIVA Biotech Holdings are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can VIVA Biotech Holdings take to modify the liabilities?

To change its liabilities, VIVA Biotech Holdings can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does VIVA Biotech Holdings pay?

Over the past 12 months, VIVA Biotech Holdings paid a dividend of 0.01 CNY . This corresponds to a dividend yield of about 1.86 %. For the coming 12 months, VIVA Biotech Holdings is expected to pay a dividend of 0 CNY.

What is the dividend yield of VIVA Biotech Holdings?

The current dividend yield of VIVA Biotech Holdings is 1.86 %.

When does VIVA Biotech Holdings pay dividends?

VIVA Biotech Holdings pays a quarterly dividend. This is distributed in the months of October, July, October, July.

How secure is the dividend of VIVA Biotech Holdings?

VIVA Biotech Holdings paid dividends every year for the past 2 years.

What is the dividend of VIVA Biotech Holdings?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is VIVA Biotech Holdings located?

VIVA Biotech Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIVA Biotech Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIVA Biotech Holdings from 7/9/2021 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 6/16/2021.

When did VIVA Biotech Holdings pay the last dividend?

The last dividend was paid out on 7/9/2021.

What was the dividend of VIVA Biotech Holdings in the year 2023?

In the year 2023, VIVA Biotech Holdings distributed 0 CNY as dividends.

In which currency does VIVA Biotech Holdings pay out the dividend?

The dividends of VIVA Biotech Holdings are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VIVA Biotech Holdings

Our stock analysis for VIVA Biotech Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VIVA Biotech Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.